Please Wait a Moment
X

Articles

10Jul

FDA Guidance for Industry for Babesia

10 Jul, 2019 | Return|

On May 9, 2019 the Food and Drug Administration issued a “Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis” guidance document with a maximum 12 month implementation timeline. Per the FDA guidance document recommendations, CTS is developing a specific implementation plan for mandatory Babesia testing well before the May 8, 2020 deadline.

 

Check out the Communication page for the complete details by clicking the link: Communications

Related

CTS Dallas Implements New Laboratory Information System

On September 23, 2019, the new CTS Laboratory Information System successfully implemented in Da...

Read More >

Confirmatory Algorithm and Assay Changes Effective September 30, 2019

On June 13, 2019, CTS provided information regarding the manufacturer’s discontinuation of HIV...

Read More >

IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization

IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization

Read More >

CTS Implements HLA Class I and II Testing on the Gemini

CTS successfully implemented Donor-Screen HLA® Class I and II testing on the Stratec Biomedical ...

Read More >

FDA Releases ZIKV Guidance and Grifols ZIKV Assay Licensed- August 8th Update

CTS communications distributed on July 6th and July 20th.In working with Grifols on the availability...

Read More >

Special Testing Laboratory Test Result Reporting Change

An exciting enhancement is implementing January 20, 2020 in our Special Testing laboratory as we mov...

Read More >